MYELOFIBROSIS
Clinical trials for MYELOFIBROSIS explained in plain language.
Never miss a new study
Get alerted when new MYELOFIBROSIS trials appear
Sign up with your email to follow new studies for MYELOFIBROSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo tested to fight rare blood cancer
Disease control TerminatedThis study tested whether adding a new drug called parsaclisib to an existing treatment (ruxolitinib) could better control myelofibrosis, a serious bone marrow cancer. It involved 252 adults with intermediate or high-risk disease who had not previously taken similar medications. …
Matched conditions: MYELOFIBROSIS
Phase: PHASE3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New drug duo aims to shrink enlarged spleens in blood cancer patients
Disease control TerminatedThis study tested a combination of two oral drugs, TQ05105 and TQB3909, for adults with moderate-to-high risk myelofibrosis, a serious bone marrow cancer. The main goals were to find a safe dose and see if the treatment could reduce spleen size and ease symptoms. The trial was te…
Matched conditions: MYELOFIBROSIS
Phase: PHASE1, PHASE2 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
New hope for blood cancer patients: trial tests combo therapy for tough cases
Disease control TerminatedThis study tested whether adding a new drug called parsaclisib to the standard treatment (ruxolitinib) could help people with myelofibrosis, a serious bone marrow cancer, who weren't getting a good enough response from ruxolitinib alone. It involved 177 participants and compared …
Matched conditions: MYELOFIBROSIS
Phase: PHASE3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Mar 17, 2026 13:09 UTC